Payment overview · 2025
General Payments
$2,099.07
99 reported records · 20 companies
Healthcare provider profile · identity verified
Chaewon Song, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · GARDEN GROVE, CA · NPI 1972589687
Verified facts
What the public records show
CMS Open Payments records show Chaewon Song, MD received $2,099.07 in general payments during 2025 across 99 reported records.
Aimmune Therapeutics, Inc. accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Gemtesa, Jardiance, Linzess, Ozempic, Prolia, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 927 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lumigan by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 436 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $599.45 | 28.6% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $506.33 | 24.1% | 35 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $151.29 | 7.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $117.62 | 5.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $116.37 | 5.5% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $58.57 | 2.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.87 | 2.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $53.97 | 2.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.86 | 2.4% | 2 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.45 | 2.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.36 | 2.3% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $47.99 | 2.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.78 | 2.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.67 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.23 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.97 | 1.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.96 | 1.2% | 1 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $24.96 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.35 | 1.2% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.02 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,099.07 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $599.45 | 25 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $506.33 | 35 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $376.88 | 24 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $173.36 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $168.48 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $70.92 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $58.57 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.87 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $53.97 | 2 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $47.99 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.78 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.45 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.45 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 927 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 436 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 193 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 222 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 92 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 318 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
927 | 154 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
222 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
318 | 53 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
92 | 58 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
167 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
193 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
193 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
436 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
51 | 51 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2757 | 529 |
| Amlodipine Besylate | Amlodipine Besylate | 2314 | 413 |
| Losartan Potassium | Losartan Potassium | 1792 | 336 |
| Metformin Hcl | Metformin Hcl | 1078 | 249 |
| Omeprazole | Omeprazole | 986 | 210 |
| Creon | Lipase/Protease/Amylase | 927 | 154 |
| Vascepa | Icosapent Ethyl | 878 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 869 | 199 |
| Tamsulosin Hcl | Tamsulosin Hcl | 838 | 162 |
| Simvastatin | Simvastatin | 798 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 794 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 789 | 167 |
| Donepezil Hcl | Donepezil Hcl | 723 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 603 | 110 |
| Gabapentin | Gabapentin | 536 | 93 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 501 | 70 |
| Lidocaine | Lidocaine | 480 | 74 |
| Hydralazine Hcl | Hydralazine Hcl | 474 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 463 | 71 |
| Furosemide | Furosemide | 447 | 95 |
| Eliquis | Apixaban | 436 | 58 |
| Celecoxib | Celecoxib | 432 | 101 |
| Potassium Chloride | Potassium Chloride | 429 | 91 |
| Memantine Hcl | Memantine Hcl | 401 | 75 |
| Diclofenac Sodium | Diclofenac Sodium | 390 | 71 |
| Azithromycin | Azithromycin | 379 | 259 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 378 | 62 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 357 | 150 |
| Finasteride | Finasteride | 352 | 65 |
| Alendronate Sodium | Alendronate Sodium | 347 | 85 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 342 | 71 |
| Zenpep | Lipase/Protease/Amylase | 318 | 53 |
| Tradjenta | Linagliptin | 311 | 47 |
| Carvedilol | Carvedilol | 294 | 50 |
| Januvia | Sitagliptin Phosphate | 286 | 35 |
| Atenolol | Atenolol | 278 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 276 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 246 | 55 |
| Meloxicam | Meloxicam | 244 | 105 |
| Glipizide | Glipizide | 242 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 239 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 233 | 54 |
| Dexlansoprazole Dr | Dexlansoprazole | 226 | 31 |
| Linzess | Linaclotide | 222 | 35 |
| Famotidine | Famotidine | 215 | 41 |
| Montelukast Sodium | Montelukast Sodium | 211 | 30 |
| Jardiance | Empagliflozin | 193 | 41 |
| Dutasteride | Dutasteride | 192 | 38 |
| Lorazepam | Lorazepam | 191 | 48 |
| Lisinopril | Lisinopril | 178 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 168 | 26 |
| Farxiga | Dapagliflozin Propanediol | 167 | 25 |
| Icosapent Ethyl | Icosapent Ethyl | 160 | 65 |
| Tramadol Hcl | Tramadol Hcl | 156 | 34 |
| Cephalexin | Cephalexin | 147 | 121 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 29 |
| Prednisone | Prednisone | 146 | 85 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 144 | 30 |
| Divalproex Sodium | Divalproex Sodium | 135 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 133 | 29 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 127 | 26 |
| Benazepril Hcl | Benazepril Hcl | 125 | 18 |
| Mirtazapine | Mirtazapine | 125 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 122 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 121 | 20 |
| Allopurinol | Allopurinol | 120 | 23 |
| Sertraline Hcl | Sertraline Hcl | 117 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 115 | 89 |
| Lovastatin | Lovastatin | 115 | 22 |
| Myrbetriq | Mirabegron | 115 | 17 |
| Fenofibrate | Fenofibrate | 106 | 21 |
| Ezetimibe | Ezetimibe | 105 | 21 |
| Repaglinide | Repaglinide | 102 | 24 |
| Metformin Hcl Er | Metformin Hcl | 101 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 21 |
| Memantine Hcl Er | Memantine Hcl | 97 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 96 | 15 |
| Prolia | Denosumab | 92 | 58 |
| Amiodarone Hcl | Amiodarone Hcl | 91 | 16 |
| Latanoprost | Latanoprost | 88 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 17 |
| Ranolazine Er | Ranolazine | 85 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 58 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 82 | 16 |
| Xarelto | Rivaroxaban | 81 | suppressed |
| Ibuprofen | Ibuprofen | 79 | 53 |
| Trulicity | Dulaglutide | 77 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 15 |
| Ozempic | Semaglutide | 76 | suppressed |
| Valsartan | Valsartan | 76 | 17 |
| Pregabalin | Pregabalin | 75 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 74 | 15 |
| Alprazolam | Alprazolam | 73 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 73 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 15 |
| Labetalol Hcl | Labetalol Hcl | 68 | 11 |
| Temazepam | Temazepam | 67 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 15 |
| Galantamine Hbr | Galantamine Hbr | 65 | 18 |
| Epogen | Epoetin Alfa | 64 | suppressed |
| Fluocinonide | Fluocinonide | 64 | 34 |
| Ketoconazole | Ketoconazole | 63 | 22 |
| Levofloxacin | Levofloxacin | 62 | 58 |
| Restasis | Cyclosporine | 60 | 14 |
| Cyclosporine | Cyclosporine | 59 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 56 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 52 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 51 | 51 |
| Clobetasol Propionate | Clobetasol Propionate | 50 | 19 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 49 | suppressed |
| Lansoprazole | Lansoprazole | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Amoxicillin | Amoxicillin | 46 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 46 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 29 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 44 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 13 |
| Jentadueto | Linagliptin/Metformin Hcl | 44 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 43 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Nitroglycerin | Nitroglycerin | 42 | 24 |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Glimepiride | Glimepiride | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 33 |
| Mupirocin | Mupirocin | 41 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Dextrose In Lactated Ringers | Dextrose 5%-Lactated Ringers | 40 | 25 |
| Trazodone Hcl | Trazodone Hcl | 40 | 11 |
| Ciclopirox | Ciclopirox | 37 | 19 |
| Procto-Med Hc | Hydrocortisone | 37 | 12 |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Glucagon Emergency Kit | Glucagon | 36 | 14 |
| Hydrocortisone | Hydrocortisone | 36 | 15 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Gemtesa | Vibegron | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 33 | suppressed |
| Loperamide | Loperamide Hcl | 33 | 18 |
| Sucralfate | Sucralfate | 32 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 30 | suppressed |
| Lactulose | Lactulose | 30 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | 11 |
| Baclofen | Baclofen | 29 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | 17 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | 18 |
| Brilinta | Ticagrelor | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 21 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Lumigan | Bimatoprost | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | 12 |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Alphagan P | Brimonidine Tartrate | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 12 |
| Ethacrynic Acid | Ethacrynic Acid | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 15 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 20 | 16 |
| Febuxostat | Febuxostat | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Travoprost | Travoprost | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Glucagon Emergency Kit | Glucagon Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 17 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | 14 |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 11 |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 15 | 15 |
| Ramipril | Ramipril | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Proctozone-Hc | Hydrocortisone | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nystatin | Nystatin | 13 | 12 |
| Olanzapine | Olanzapine | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vyzulta | Latanoprostene Bunod | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,099.07 · 99 records | Aimmune Therapeutics, Inc. | AIRSUPRA, AREXVY, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FUROSCIX, GEMTESA, IBSRELA, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, OTEZLA, Ozempic, PANCREAZE, PROLIA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VELPHORO, XIFAXAN, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error